CRISPR Therapeutics (NASDAQ: CRSP) reported Q4 EPS of ($0.44), $0.79 better than the analyst estimate of ($1.23). Revenue for the quarter came in at $35.69 million versus the consensus estimate of $7.63 million.

For earnings history and earnings-related data on CRISPR Therapeutics (CRSP) click here.